Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

vulvar intraepithelial neoplasia (VIN) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

vulvar intraepithelial neoplasia

MONDO:0005198

Also known as:VINintraepithelial neoplasia of the vulvaintraepithelial neoplasia of vulva

Find Clinical TrialsTrials

Overview

Intraepithelial neoplasia of the vulvar squamous epithelium. There is no evidence of invasion. This category includes vulvar high grade squamous intraepithelial lesion and vulvar intraepithelial neoplasia, differentiated type.

TreatmentsNo approved treatments · 2 in pipeline

Clinical Trials1 registered

Diagnosis

Biomarker and diagnostic research for vulvar intraepithelial neoplasia has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for vulvar intraepithelial neoplasia. An additional 2 compounds hold orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for vulvar intraepithelial neoplasia, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for vulvar intraepithelial neoplasia. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Prognosis

Estimated prevalence: 1-5 in 10,000 (Uncommon).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.

99 publications have been identified in PubMed for vulvar intraepithelial neoplasia. Research spans Review / Meta-Analysis (25%), Diagnostic / Biomarker (22%), and Case Report / Case Series (20%).

Research Type	Count	% of Total
Research summaries	25	25%

Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 10:16 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:137583

GARD

Genetic and Rare Diseases Info Center

GARD:19876

Questions for Your Care Team

→Are any of the 1 active clinical trial a good fit for my situation?
→What is the current development status of artesunate, and when might it become available?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

vulvar intraepithelial neoplasia

Overview

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications